Literature DB >> 15372080

Passive antibody therapy for infectious diseases.

Arturo Casadevall1, Ekaterina Dadachova, Liise-anne Pirofski.   

Abstract

Antibody-based therapies are currently undergoing a renaissance. After being developed and then largely abandoned in the twentieth century, many antibody preparations are now in clinical use. However, most of the reagents that are available target non-infectious diseases. Interest in using antibodies to treat infectious diseases is now being fuelled by the wide dissemination of drug-resistant microorganisms, the emergence of new microorganisms, the relative inefficacy of antimicrobial drugs in immunocompromised hosts and the fact that antibody-based therapies are the only means to provide immediate immunity against biological weapons. Given the need for new antimicrobial therapies and many recent technological advances in the field of immunoglobulin research, there is considerable optimism regarding renewed applications of antibody-based therapy for the prevention and treatment of infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15372080     DOI: 10.1038/nrmicro974

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  201 in total

Review 1.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 2.  Therapeutic proteins.

Authors:  Dimiter S Dimitrov
Journal:  Methods Mol Biol       Date:  2012

3.  Therapeutic antibodies, vaccines and antibodyomes.

Authors:  Dimiter S Dimitrov
Journal:  MAbs       Date:  2010-05-14       Impact factor: 5.857

4.  Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

Review 5.  Immunoglobulin class-switch DNA recombination: induction, targeting and beyond.

Authors:  Zhenming Xu; Hong Zan; Egest J Pone; Thach Mai; Paolo Casali
Journal:  Nat Rev Immunol       Date:  2012-06-25       Impact factor: 53.106

6.  Potent In Vitro and In Vivo Activity of Plantibody Specific for Porphyromonas gingivalis FimA.

Authors:  Young-Suk Choi; Ji-Hoi Moon; Tae-Geum Kim; Jin-Yong Lee
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

7.  Staphylococcus aureus virulence attenuation and immune clearance mediated by a phage lysin-derived protein.

Authors:  Hang Yang; Jingjing Xu; Wuyou Li; Shujuan Wang; Junhua Li; Junping Yu; Yuhong Li; Hongping Wei
Journal:  EMBO J       Date:  2018-07-23       Impact factor: 11.598

8.  Lysostaphin Lysibody Leads to Effective Opsonization and Killing of Methicillin-Resistant Staphylococcus aureus in a Murine Model.

Authors:  Assaf Raz; Anna Serrano; Maneesha Thaker; Tricia Alston; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

9.  Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy.

Authors:  Anne G Savitt; Patricio Mena-Taboada; Gloria Monsalve; Jorge L Benach
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

10.  Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.

Authors:  Marcio L Rodrigues; Li Shi; Eliana Barreto-Bergter; Leonardo Nimrichter; Sandra E Farias; Elaine G Rodrigues; Luiz R Travassos; Joshua D Nosanchuk
Journal:  Clin Vaccine Immunol       Date:  2007-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.